Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study

The optimal duration of dual antiplatelet therapy (DAT) after coronary stenting remains poorly define. The aim of this study was to evaluate the impact of longer than 24 months DAT in patients who received drug-eluting and bare-metal stents. A total of 1010 individuals who underwent elective, urgent...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadjou, Yahya, Safavi, Salar, Kojuri, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900702/
https://www.ncbi.nlm.nih.gov/pubmed/27258494
http://dx.doi.org/10.1097/MD.0000000000003663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900702/
https://www.ncbi.nlm.nih.gov/pubmed/27258494
http://dx.doi.org/10.1097/MD.0000000000003663

Ejemplares similares